

September 27, 2024

Joe Shia, Regulatory Affairs LSI International Inc 504 E Diamond Ave Suite H Gaithersburg, MD 20877 USA

Re: CR240515

CLIA Parent(s): k234006

Applicant: AllSource Screening Solutions

Device: A47 Drug Detector FenTest; A47 Drug Detector Fentanyl Test

Dated: August 27, 2024 Received: August 27, 2024

CLIA Effective Date: September 27, 2024

## Categorization Notification (Waived)

Regulations codified at 42 CFR 493.15 et. seq., implementing the Clinical Laboratory Improvement Amendments of 1988, require the Secretary to provide for the categorization of specific clinical laboratory test systems by the level of complexity. Based upon these regulations, the following commercially marketed test system or assay for the analyte is categorized below:

## **Test System/Analyte(s):** (SEE ATTACHMENT)

Waived status is applicable to test systems and their instructions approved by the FDA. We recommend that the test system instructions include a statement that the test system is waived under CLIA. Any modification to the test system including test system instructions or a change in the test system name must be submitted to the FDA for the evaluation of waiver. If you change the test system name or your company's name or if a distributor's name replaces your name, you must request another categorization by sending in the revised labeling along with a letter to FDA referencing the document number above.

This complexity categorization is effective as of the date of this notification and will be reported in FDA's CLIA Database: <a href="http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCLIA/search.cfm">http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCLIA/search.cfm</a>. This categorization information may be provided to the user of the commercially marketed test system or assay as specified for the analyte indicated. FDA reserves the right to re-evaluate and re-categorize this test based upon additional information received.

If you have any questions regarding this complexity categorization, please contact Xiaofen Huang at xiaofen.huang@fda.hhs.gov.

Sincerely yours,

Courtney H. Lias, Ph.D. Acting Office Director

Count Her

OHT7: Office of In Vitro Diagnostics, Office of Product Evaluation and Quality Center for Devices and Radiological Health

## Parent Number: k234006

Test System : AllSource Screening Solutions, A47 Drug Detector FenTest

Analyte : Fentanyl Complexity : WAIVED

Test System : AllSource Screening Solutions, A47 Drug Detector Fentanyl Test

Analyte : Fentanyl Complexity : WAIVED